logo-loader
Synairgen PLC

Synairgen phase II study making encouraging progress

The company is trialling an inhaled interferon beta treatment in lung disease patients who are also suffering from either a cold or flu

researcher filling a vial
In all 15 centres are up and running for the trial, which will take in the 2019/20 “virus season”

Synairgen plc (LON:SNG) appears to be making encouraging early progress with its inhaled interferon beta treatment, which is currently undergoing a phase II clinical trial.

The study will assess the drug’s potential to treat people with a progressive lung disease called COPD that also have confirmed common cold and influenza virus infections.

These exacerbations, as they are called, pose significant health risks, particularly in the winter virus season.

Chief executive Richard Marsden said the company is “successfully capturing marked changes” in patients with COPD that also have the aforementioned viruses.

15 centres up and running 

In all 15 centres are up and running for the trial, which will take in the 2019/20 “virus season” with participants screened specifically to assess whether they have cold or flu.

The test ensures that only people for whom the IFN-beta therapy may be effective are dosed, thereby increasing the chance of success.

"Aided by the rapid point-of-care test, the trial is successfully capturing marked changes in COPD symptoms in patients with confirmed common cold and influenza virus infections,” said CEO Marsden.

“We have previously shown that inhaled IFN-beta boosts the lungs' antiviral defences in COPD patients and the magnitude of the symptom changes being observed so far in the current trial puts us in a good position to determine the potential benefit of inhaled IFN-beta in this patient population."

The shares rose 6.3% to 11p.

---Adds share price---

Quick facts: Synairgen PLC

Price: 8.2 GBX

Market: AIM
Market Cap: £8.97 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Synairgen's phase II trial on lead COPD drug 'progressing well'

Synairgen PLC's (LON:SNG) Richard Marsden tells Proactive London's Andrew Scott  the respiratory drug discovery and development company, is well-poised to complete the phase II trial on its lead candidate. The trial is expected to complete dosing in Q1 next year with results available in...

2 weeks, 6 days ago

2 min read